MREO: Deadline Alert for Investors in Class Action!

Company Overview

Mereo BioPharma Group plc (NASDAQ: MREO) is a UK-based clinical-stage biopharmaceutical company focused on developing therapeutics for rare diseases and oncology (media.mereobiopharma.com). Its lead asset has been setrusumab (also known as UX143) for the treatment of osteogenesis imperfecta (OI, a rare bone disease) – a program developed in partnership with Ultragenyx Pharmaceutical (www.mereobiopharma.com). Mereo’s pipeline also includes alvelestat, a clinical-stage therapy for alpha-1 antitrypsin deficiency-related lung disease, among other earlier-stage or partnered candidates (breakthroughinvestors.com) (www.mereobiopharma.com). Like many biotech peers, Mereo has operated at a loss since inception, with an accumulated deficit of ~$462.9 million as of year-end 2024 (breakthroughinvestors.com). The company has funded its R&D and operations through periodic equity raises, convertible debt financings, and collaboration agreements (rather than any product revenues to date) (breakthroughinvestors.com). In late 2025, Mereo’s outlook was shaken by negative Phase 3 trial results on its lead OI drug, which caused an ~88% collapse in the stock price (www.globenewswire.com). This outcome has in turn triggered shareholder class-action lawsuits alleging that management misled investors about the prospects of those trials (www.globenewswire.com) (breakthroughinvestors.com). Below, we examine Mereo’s dividend policy, financial leverage, liquidity, valuation, and the key risks and questions facing the company.

Dividend Policy & AFFO/FFO

Dividend History: Mereo has never paid a dividend on its ordinary shares and explicitly does not anticipate paying cash dividends in the foreseeable future (www.sec.gov). As a pre-revenue biotech, the company retains all capital to fund development of its drug pipeline rather than returning cash to shareholders (www.sec.gov). Moreover, under UK law Mereo cannot pay dividends without sufficient distributable profits, which it lacks given its large accumulated losses (www.sec.gov). Consequently, the dividend yield is 0%, and investors should not expect any income from this stock for the foreseeable future.

AFFO/FFO: Metrics like Funds From Operations (FFO) or Adjusted FFO (AFFO) – commonly used for REITs and other income-producing assets – are not applicable to Mereo. The company generates no recurring operating cash flow or earnings (product revenue was essentially zero in recent years) and instead reports significant net losses (media.mereobiopharma.com) (media.mereobiopharma.com). In fact, Mereo’s operations consume cash rather than produce funds for distribution. The absence of any positive FFO/AFFO underscores that MREO’s valuation is based on future pipeline potential rather than current income generation. Investors in MREO are effectively betting on the success of drug development milestones, not on any near-term cash flows.

Leverage & Debt Maturities

Convertible Notes: Mereo’s balance sheet now carries minimal debt, after recent conversions of its outstanding notes into equity. In prior years, the company issued various convertible loan notes – notably a £3.8 million note to Novartis in 2020 (with attached warrants) that was originally due Feb 10, 2023 (breakthroughinvestors.com). This Novartis note’s maturity was later extended to Feb 10, 2025 (with a higher 9% interest rate) (breakthroughinvestors.com). On February 7, 2025, shortly before maturity, Novartis exercised its conversion option: Mereo converted the entire principal and accrued interest into equity, issuing approximately 17.1 million new ordinary shares (3.42 million ADSs) to Novartis (breakthroughinvestors.com). On the same day, Novartis also exercised its remaining warrants, purchasing ~1.45 million additional shares for $0.5 million in cash (breakthroughinvestors.com). As a result, the Novartis loan was fully retired via equity issuance rather than cash repayment.

Private Placement Notes: In addition to the Novartis loan, Mereo had issued other convertible loan notes through private placements. During 2023, notes with a carrying value around $7.5 million were outstanding; these too were converted into equity (about 27.42 million ordinary shares at £0.174/share) between June and August 2023 (breakthroughinvestors.com). These conversions eliminated what had been short-term debt coming due in 2023. After the retirement of both the Novartis note and the private notes, Mereo was left with no significant interest-bearing debt outstanding by early 2025 (breakthroughinvestors.com) (breakthroughinvestors.com). The remaining liabilities on its balance sheet are limited to non-debt items like lease obligations and warrant liabilities, which are relatively small (breakthroughinvestors.com).

Debt Maturities: With the convertible bonds effectively exchanged for stock, Mereo faces no imminent debt maturities in the near term. The last major maturity was in February 2025 (the Novartis note), and that obligation was settled via share conversion (breakthroughinvestors.com). Any future financing needs are thus likely to be met with new equity raises or partnering deals rather than debt. This deleveraged position means Mereo currently avoids repayment or default risk, though it has come at the cost of significant dilution to existing shareholders.

Coverage & Liquidity

Interest Coverage: With its debt eliminated, Mereo’s interest expense is now minimal, so traditional interest coverage ratios (EBIT/interest) are not a concern. Before conversion, the Novartis note’s 9% interest was accruing, but accrued interest up to the extension was paid in cash, and remaining interest was effectively eliminated by the conversion in 2025 (breakthroughinvestors.com) (breakthroughinvestors.com). Removing debt has freed Mereo from interest payments and covenant constraints. However, fixed-charge coverage in a broader sense (ability to cover fixed obligations) still depends on the company’s cash burn and operating expenses, since it must fund R&D and overhead from its cash reserves.

Cash Position & Runway: Liquidity is a critical issue for Mereo. The company’s cash and equivalents were $69.8 million as of December 31, 2024 (media.mereobiopharma.com), bolstered by a $47 million equity raise completed in mid-2024. By September 30, 2025, cash had declined to $48.7 million (www.mereobiopharma.com) as the company continued funding its trials and operations. Management projected in late 2025 that this cash was sufficient to support operations into 2027 based on current plans (www.mereobiopharma.com). In other words, at the Q3 2025 burn rate (roughly $6–7 million per quarter), Mereo had around 6–8 quarters of runway remaining. Investors should monitor the cash burn relative to this runway in coming quarters, especially as the company pivots strategy after the recent trial setbacks.

Funding Sources: With no product revenue, Mereo’s ability to remain liquid hinges on external financing and partnership inflows. The company has been successful in securing collaboration payments in the past (e.g. from Ultragenyx and others) and tapping equity markets when needed. Looking ahead, any new clinical programs or trials (such as a Phase 3 for alvelestat) would require substantial capital – highlighting the importance of either finding a development partner or raising additional funds before cash runs low. Mereo’s current cash balance, while enough for near-term needs, does not eliminate the need for future financing if the pipeline is to advance toward commercialization.

Valuation Metrics and Outlook

Traditional valuation metrics are difficult to apply to MREO given its lack of positive earnings and early-stage pipeline:

– Earnings/FFO Multiples: Mereo has no positive net income or FFO, so metrics like P/E or P/FFO are not meaningful. The company’s value hinges entirely on expectations for its drug pipeline rather than current financial performance. Notably, Mereo’s ADS price plunged from $2.31 to $0.29 in one trading day (Dec 29, 2025) after news of the Phase 3 failures (www.prnewswire.com). This -87.7% one-day collapse erased nearly 88% of the stock’s value, reflecting a severe market reassessment of the company’s prospects (www.globenewswire.com). It underscores how sensitive the valuation is to clinical outcomes.

– Market Capitalization & Cash: At roughly $0.30 per share in early 2026 (post-crash), MREO’s market capitalization stands on the order of only a few tens of millions of dollars. This is not much higher than the cash on its balance sheet. For example, with around 160 million ADS equivalent shares outstanding (each ADS represents 5 ordinary shares) after the conversions, a ~$0.30 ADS price implies a market cap near $50 million. Over one-quarter of that market cap is actually backed by net cash (~$50 million as of Q3 2025), meaning the market is valuing Mereo’s enterprise (pipeline and other assets) at only around $0 – essentially at or below liquidation value. (Before the crash, at ~$2.50/share, Mereo’s market cap was over $300 million, a valuation that has now been virtually wiped out.) The current low valuation suggests that investors are highly skeptical about the remaining pipeline, assigning little value to the company’s drug candidates in the wake of the recent failure.

– Price/Book Ratio: Mereo’s book value consists mainly of its cash holdings (plus some intangible assets from acquired programs). Shareholders’ equity was about $61 million as of Dec 31, 2024 (media.mereobiopharma.com). At ~$0.30 per share, the stock now trades roughly at book value (1.0x P/B) – or even at a discount depending on post-2024 losses – whereas it traded at many times book value prior to the trial failure. This collapse toward book/cash value indicates that the market has radically lowered its expectations for future cash flows or asset commercialization. Essentially, MREO now trades as if its pipeline is worth very little beyond the cash it has in hand, whereas earlier it had a significant speculative premium.

– Comparables: Among small-cap biotechs focused on rare diseases (with no approved products), it is common to see market caps gravitate toward cash value when confidence in the pipeline falters. Peers that suffer a major Phase 3 failure and have no other near-term assets often end up trading near or below their net cash levels. In Mereo’s case, the fact that its market cap still slightly exceeds its cash (implying a modest ~$0 value to pipeline) suggests the market hasn’t completely written off its remaining programs. That said, the sentiment is clearly depressed. Conventional valuation metrics offer little clarity here – MREO’s future value will depend on binary milestone events (partnering deals, clinical trial readouts, etc.) rather than on predictable earnings or cash flow ratios. The stock’s collapse after ORBIT/COSMIC illustrates how pivotal clinical data is to valuation: pipeline outcomes dictate the company’s value far more than any current financial metrics (breakthroughinvestors.com).

Key Risks & Red Flags

Trial Failures: The most immediate risk is the sharp deterioration of Mereo’s pipeline value after the failure of its lead program. On December 29, 2025, Mereo announced that its two Phase 3 trials (ORBIT and COSMIC) of setrusumab in OI failed to meet their primary endpoints, as neither showed a statistically significant reduction in fracture rate versus placebo or the active control (bisphosphonate) (breakthroughinvestors.com). Although patients on setrusumab did exhibit improved bone mineral density, the lack of fracture reduction calls into question the drug’s real-world efficacy (breakthroughinvestors.com). This was a devastating outcome for a program that had been the company’s main value driver. Ultragenyx, Mereo’s partner that had been leading and funding these studies, is now unlikely to continue development of setrusumab given the results, leaving that asset’s fate unclear. The stock’s nearly 88% crash on the news (breakthroughinvestors.com) highlights how central setrusumab was to Mereo’s valuation. Pipeline concentration risk remains high – beyond setrusumab, Mereo’s portfolio is limited (alvelestat is now the lead asset, with other programs either early-stage or already partnered out). If confidence in alvelestat were to falter, the company would have very little else to fall back on.

Securities Litigation: In the wake of the trial failure, multiple shareholder rights law firms (including Rosen, Robbins LLP, Levi & Korsinsky, and others) have filed or announced class-action lawsuits against Mereo, alleging that the company misled investors about the ORBIT and COSMIC trials. The complaints claim that management provided overly positive statements to investors in 2023–2025 – expressing confidence that setrusumab would reduce fracture rates and achieve significance – while concealing material adverse facts about the true state of those studies (natlawreview.com) (natlawreview.com). For example, executives reportedly assured investors of their confidence in the trials’ success even as the studies were ultimately doomed to miss their key endpoint (natlawreview.com). The class period in these suits (June 5, 2023 through Dec 26, 2025) covers the timeframe during which optimistic updates were given, up until the negative results were disclosed (www.prnewswire.com). Once the bad news hit, the stock plunged – allegedly causing significant investor losses (www.prnewswire.com). This legal action is a red flag regarding management’s credibility and transparency. If the allegations have merit, they suggest poor internal disclosure practices or even intentional deceit. Even if Mereo denies wrongdoing, the litigation could distract management and may eventually lead to settlement costs or damages (though typically such cases are covered by D&O insurance). Importantly, these events may damage investor trust, and any reputational hit could make it harder for the company to raise capital or attract partners in the future.

Continued Losses & Dilution: Mereo has never been profitable and will continue to incur operating losses for the foreseeable future (breakthroughinvestors.com). With essentially no product revenue on the horizon, the company must keep funding R&D and administrative costs from its cash reserves. While it currently has cash for perhaps ~2 years of operations, eventually dilution risk looms: unless a major partnership or licensing deal provides non-dilutive funding, Mereo will likely need to raise more equity capital. Any new stock issuance (or warrants, etc.) would further dilute existing shareholders – on top of the heavy dilution already seen from the recent note conversions and past offerings. Mereo’s share count has ballooned to roughly 800 million ordinary shares outstanding (equivalent to ~160 million ADSs) after successive fundraises and debt-to-equity swaps (breakthroughinvestors.com). If the company cannot secure other funding sources, shareholders may see additional dilution to extend the cash runway or to finance expensive trials (e.g. a Phase 3 program for alvelestat). This structural dilution risk is common in small biotech firms and remains a key concern for MREO investors.

Regulatory & Development Risks: Even the remaining pipeline assets carry substantial risk. Alvelestat, now Mereo’s primary asset, has yet to enter Phase 3 testing for alpha-1 antitrypsin deficiency. There is no guarantee that the Phase 3 trial (once started) will succeed clinically or lead to regulatory approval – many drug candidates fail in late-stage trials due to efficacy or safety issues. Moreover, as a rare disease program, enrolling and executing a Phase 3 for alvelestat could be challenging and costly, and success will depend on finding a partner or obtaining funding. Beyond alvelestat, Mereo’s other programs (such as an oncology candidate, or earlier-stage rare disease assets like vantictumab licensed to ōAshibio) are not near commercialization and in some cases rely on partners to advance. The company’s focus on rare diseases means regulatory pathways (like orphan drug approvals) can be expedited, but also that market sizes are smaller and trial designs may have to surmount significant variability. Any setbacks in remaining programs (clinical trial failures, FDA regulatory hurdles, delays in starting new studies, etc.) would further erode the bull case for the stock. In short, Mereo still faces all the typical development-stage biotech risks: uncertain science, regulatory challenges, and the constant need for capital to fuel R&D.

Governance & Strategic Uncertainty: It’s worth noting that Mereo came under pressure from activist shareholders in the past (e.g. in 2022, Rubric Capital launched a campaign pushing for strategic changes) (fintel.io) (fintel.io). In response, the company undertook cost-cutting measures – targeting a 40% reduction in headcount and other expense cuts to extend its cash runway into 2026 (fintel.io). While those actions helped reduce cash burn (general & administrative expenses fell nearly 30% from 2022 to 2023), the recent events raise new questions about leadership. The fact that multiple trials failed and that lawsuits allege management misled investors could embolden activist investors or new voices to demand changes (board refresh, asset sales, tighter spending, etc.). Mereo’s management and board will be under scrutiny to demonstrate that they can steer the company through this crisis. Any missteps in governance or strategy (for example, persisting with a hopeless project, or failing to secure partnerships) would be another red flag for investors.

Open Questions and What to Watch

The coming months will be critical for Mereo. Key open questions include:

– **Can Mereo secure a partner or new funding for alvelestat? The company has indicated it is actively in partnering discussions for alvelestat (www.mereobiopharma.com). A partnership deal could bring in much-needed upfront cash and external validation of the drug’s potential. If no partner is found, will Mereo attempt to finance a Phase 3 trial on its own – which would significantly deplete its cash – or will it delay the program? The outcome of these partnering efforts will determine how the remaining cash is deployed and how much further dilution might be necessary. Investors should watch for any licensing or co-development announcements regarding alvelestat, as this will be a pivotal decision point.

– What is the fate of setrusumab (UX143) after the Phase 3 failure? Following the ORBIT and COSMIC trial disappointments, it’s unclear if any viable path forward remains for setrusumab in osteogenesis imperfecta. Will Mereo and Ultragenyx conduct further analyses or perhaps explore a modified trial (for instance, targeting a specific subset of OI patients or a different endpoint like quality-of-life or bone density)? Or is the program effectively dead in the water? Clarity on whether the observed bone density gains could support some limited use, or if any “salvage” strategy exists (such as a small study to see if fractures reduce over a longer period or in younger patients), is an open question. If the asset is abandoned entirely, Mereo loses its most advanced program – but conversely, discontinuing it might allow the company to cut associated costs (trials, pre-commercial activities) and conserve cash. Any communications from Ultragenyx or Mereo about analyses of the Phase 3 data or decisions on setrusumab will be important to monitor.

– How will Mereo deploy its $40–50 million in cash now? With a drastically reduced market cap, Mereo could be seen as a cash-rich shell relative to its size. Will management adopt a very defensive stance – conserving cash aggressively (given the pipeline setback) to extend the runway as long as possible? Or will they seek to rebuild value by acquiring or in-licensing new drug candidates to fill the pipeline gap left by setrusumab? There’s a strategic trade-off here: hunkering down and preserving capital vs. making a bold move to try to pivot the company’s focus. In extreme cases, if no attractive opportunities are available, one could even question whether returning value to shareholders (e.g. via a share buyback or special dividend from the cash reserves) might be considered – though that seems unlikely while the company still has development-stage ambitions. Investors will be watching for any hints in upcoming communications (earnings calls, press releases) about Mereo’s capital allocation plans in light of the trial failure.

– Will there be further cost cuts or restructuring? Companies facing major setbacks often streamline their operations. Mereo had already been in cost-cut mode (recall the 2022 plan to cut headcount by up to 40% to reduce expenses) (fintel.io). Given the new reality, we may see additional cuts in R&D programs, staff, or overhead to preserve cash. Will Mereo maintain its current organizational footprint, or will it scale down to a smaller operation? A drastic option would be exploring a strategic transaction – for instance, merging with another biotech or selling off certain assets – if management believes shareholders might be better served by such a move. Any announced restructuring, layoffs, or strategic reviews would signal how management is adapting the company’s cost structure to its changed prospects.

– What will be the outcome of the class-action lawsuit, and what information will emerge? The lead plaintiff filing deadline is April 6, 2026 for the securities class action (www.prnewswire.com). The legal process will likely take time (perhaps years), and most securities cases end in settlements. However, a key question is whether Mereo will opt for an early settlement to limit publicity, or fight the claims in court. If the case proceeds, there may be discovery of internal documents and emails about the ORBIT/COSMIC trials. Investors should watch whether any damaging information comes out that further erodes trust in management. Conversely, a swift resolution or dismissal of the case could remove an overhang. While the direct financial impact of the lawsuit might be covered by insurance, any admissions or findings could influence Mereo’s governance going forward. Also, it will be telling if the company takes any steps to improve its disclosure practices or governance in response (for example, adding new clinical oversight committees or enhancing risk disclosures).

– Can Mereo remain in compliance with Nasdaq listing requirements? MREO’s ADS now trades well below the Nasdaq’s $1.00 minimum bid price requirement. If the share price remains under $1 for an extended period (typically 30 consecutive trading days), Mereo will receive a non-compliance notice – if it hasn’t already in early 2026. The company would then likely have 180 days (or more, if an extension is granted) to cure the deficiency, for example by getting the stock back above $1 for at least 10 trading days in a row (www.biospace.com) (www.nasdaq.com). If the stock does not naturally recover, Mereo might resort to a reverse stock split to boost the nominal share price. Given the already huge share count (~800 million ordinaries), a reverse split could be a logical step to both regain compliance and reduce the number of shares to a more manageable level. Investors should be alert for any announcements regarding Nasdaq compliance or shareholder votes on a reverse split, as these will affect the stock’s trading dynamics (though not the underlying value).

In conclusion, Mereo BioPharma faces a challenging road ahead. The upcoming class-action deadline and lawsuit underscore investor unrest following the late-2025 collapse of its lead program. With no dividend cushion or steady cash flows, MREO remains a high-risk, high-reward bet hinging on management’s next strategic moves. Investors should keep a close eye on partnership news, pipeline updates, and strategic decisions that could signal a turnaround (or lack thereof). Mereo’s ability to navigate these uncertainties – securing deals, cutting costs, and maybe reviving its pipeline – will determine whether the company can eventually restore some of its lost shareholder value, or continues to languish under the weight of its setbacks.

Sources:** Mereo BioPharma SEC filings, investor presentations and press releases; Nasdaq listing regulations; and class-action lawsuit announcements (www.sec.gov) (www.mereobiopharma.com) (www.prnewswire.com) (breakthroughinvestors.com) (natlawreview.com) (fintel.io). (All inline citations above reference the specific sources of data and statements.)

For informational purposes only; not investment advice.